Ocuphire Pharma (OCUP) News and press releases

HC Wainwright & Co. Reiterates Buy on Ocuphire Pharma, Maintains $20 Price Target

31 Mar 23

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Matthew Caufield reiterates Ocuphire Pharma (NASDAQ:OCUP) with a Buy and maintains $20 price target.

Ocuphire Pharma Q4 EPS $1.63 Beats $0.97 Estimate, Sales $39.85M Beat $29.44M Estimate

30 Mar 23

Earnings, News

Ocuphire Pharma (NASDAQ:OCUP) reported quarterly earnings of $1.63 per share which beat the analyst consensus estimate of $0.97 by 68.04 percent. This is a 565.71 percent increase over losses of $(0.35) per share from

HC Wainwright & Co. Reiterates Buy on Ocuphire Pharma, Maintains $20 Price Target

17 Feb 23

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Matthew Caufield reiterates Ocuphire Pharma (NASDAQ:OCUP) with a Buy and maintains $20 price target.

Ocuphire Announces APX3330 Phase 2 Data Presentations At Retina Meetings

16 Feb 23

Biotech, News, FDA, General

Topline Data from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy Presented on February 11th at 20th Angiogenesis, Exudation, and Degeneration 2023 Meeting Topline Data from ZETA-1 Accepted

12 Health Care Stocks Moving In Monday's Pre-Market Session

13 Feb 23

Movers

12 Health Care Stocks Moving In Friday's After-Market Session

27 Jan 23

Movers

Why Panbela Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

26 Jan 23

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers MicroAlgo Inc. (NASDAQ: MLGO) shares jumped 74% to $2.90. MicroAlgo recently entered into securities purchase agreement for up to $3.2 million.

12 Health Care Stocks Moving In Thursday's Intraday Session

26 Jan 23

Movers

Nasdaq Surges 100 Points; Tesla Beats Q4 Views

26 Jan 23

Earnings, News, Penny Stocks, Eurozone, Commodities, Global, Intraday Update, Markets

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.24% to 33,824.53 while the NASDAQ rose 1.05% to 11,432.45. The S&P 500 also rose, gaining, 0.54% to 4,037.88.

12 Health Care Stocks Moving In Thursday's Pre-Market Session

26 Jan 23

Movers

HC Wainwright & Co. Maintains Buy on Ocuphire Pharma, Lowers Price Target to $20

26 Jan 23

News, Price Target, Analyst Ratings

HC Wainwright & Co. analyst Matthew Caufield maintains Ocuphire Pharma (NASDAQ:OCUP) with a Buy and lowers the price target from $26 to $20.

12 Health Care Stocks Moving In Wednesday's After-Market Session

25 Jan 23

Movers

Ocuphire Pharma Announces First Patient Enrolled In VEGA-2 Pivotal Phase 3 Trial Of Nyxol In Presbyopia

9 Jan 23

Biotech, News, FDA, General

Nyxol® Eye Drops Potentially Offer Differentiated Mechanism of Action to Treat Age-Related Blurry Near Vision Launch of Presbyopia Phase 3 Program Supported by Positive Clinical Results that Demonstrated

Ocuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate Update

30 Mar 23

Earnings, Press Releases

Financial Profile Improved Markedly with Global License Agreement to Develop and Commercialize Nyxol for All Three Indications with Cash Runway into 2025 PDUFA Date of September 28, 2023 Set for Nyxol® in its First

Ocuphire Announces APX3330 and Nyxol® Data Presentations at ARVO 2023 Annual Meeting

23 Mar 23

News, Health Care, Press Releases

Oral Presentation to Feature Results from ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy Patients Results from Phase 3 LYNX-1 Trial of Nyxol® in Dim Light Vision Disturbance to be Presented for the

Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetings

16 Feb 23

News, Press Releases

Topline Data from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy Presented on February 11th at 20th Angiogenesis, Exudation, and Degeneration 2023 Meeting Topline Data from ZETA-1 Accepted for

Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA

25 Jan 23

Health Care, Press Releases

Oral APX3330 Achieved Statistical Significance on a Key Pre-specified Secondary Endpoint of Preventing Clinically Meaningful Progression of Diabetic Retinopathy (DR) after 24 Weeks of Treatment Oral APX3330